atients, uncertainties about the timely performance
of third parties, and whether the Company's products will demonstrate
safety and efficacy. Additional information on these and other factors,
which could affect the Company's results, is included in its Securities and
Exchange Commission ("SEC") filings, including in the Risk Factors section
of the Company's Annual Report on Form 10-K for the year ended December 31,
2007 and in its recently filed Form S-1. Finally, there may be other
factors not mentioned above or included in the Company's SEC filings or
recently filed Form S-1 that may cause actual results to differ materially
from those projected in any forward-looking statement. You should not place
undue reliance on any forward-looking statements. The Company assumes no
obligation to update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.
'/>"/>SOURCE Northwest Biotherapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer2.
Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics3.
Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference4.
Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast5.
Northwest Secures US$4.0 Million in Debt Financing6.
Nikon Instruments Opens New Imaging Center at Northwestern University7.
Northwestern chemist investigates lost reds in Homer painting8.
Northwest Biotherapeutics to Present at Next Generation Vaccine Conference9.
Northwestern chemists take gold, mass-produce Beijing Olympic logo10.
Northwest Secures US$1.0 Million Debt Financing11.
Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices